MedTrace Logo

Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours

NCT01859351 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2014-05-16

No results posted yet for this study

Summary

The purpose of this study is to test the safety of escalating doses of the novel PI3K inhibitor WX-037 and to explore its effectiveness in combination with WX-554 which targets mitogen activated protein kinase (MEK1 and MEK2). Preclinical evidence indicates that these two novel compounds could provide targeted inhibition of both pathways to block tumour growth.

Conditions

  • Advanced Solid Tumours

Interventions

DRUG

WX-037

DRUG

WX-554

Sponsors & Collaborators

  • Heidelberg Pharma AG

    lead INDUSTRY

Principal Investigators

  • Udai Banerji, MD · Royal Marsden NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01859351 on ClinicalTrials.gov